Scott Christensen, MD
Medical Director, Rideout Cancer Center; Medical Director, UC Davis Cancer Care Network; Professor, Hematology/Oncology, UC Davis School of Medicine.
Excerpted from the Rideout Cancer Center Annual Report, September 2010
I am pleased to report continued success and advancement for the Rideout Cancer Center. Our achievements represent the invaluable contributions of staff, donors, and individuals within our community.
2010 represents a significant milestone in Rideout Cancer Center's history: Our 10th Anniversary! It is remarkable to reflect on the achievements of the past ten years beginning with the creation of an unparalleled environment for the delivery of truly comprehensive cancer care. We have become accredited by the American College of Surgeons as a Community Cancer Program. We participated as a founding member of the UC Davis Cancer Care Network. Today, we find our services have outgrown our current space and we are excited for an upcoming expansion that will enhance clinic and infusion space, infusion space, and provide for increased technological sophistication.
We continue to experience continued growth in referrals and consultations. In the past year, over 800 new patients were referred to the Cancer Center - over 550 to Medical Oncology and over 250 to Radiation Oncology. In total, the Rideout Cancer Center provided consultative and ongoing care for over 28,500 patient visits. Breast, lung, colorectal and prostate cancers continue to account for the majority of the patient referrals.
Our greatest strength is our staff. Our physicians have been honored with several awards this year, our nursing personnel continue to increase their standards of excellence, and our administrative staff has continued to effectively manage the daily difficulties so pervasive in this difficult health care environment. I am particularly proud of our continued ability to deliver quality care to our community despite significant financial challenges. We were able to provide over two million dollars in uncompensated care in the current fiscal year.
I anticipate even greater success for the Rideout Cancer Center in its next ten years. We are expanding our clinical trials program with the addition of another clinical research coordinator that will allow greater accrual to state of the art therapies. Our expertise in oncologic subspecialties continues to be enhanced by participation in Cancer Care Network Virtual Tumor Boards. We will expand Radiation Oncology capabilities by the addition of another advanced linear accelerator, and the location of a new PET imaging system within the Cancer Center for diagnostic and treatment planning purposes. With the completion of a much needed addition to Rideout Hospital, we will begin the organization of an inpatient oncology-focused unit that will significantly expand our treatment options within the Rideout Health Group.
I continue to be amazed and humbled by the generosity and support of our community in its support of the Rideout Cancer Center. Without the vision, determination and tenacity of many individuals and groups, the past ten years would have been remarkably different. Perhaps most importantly, I thank the patients who place their faith and trust in us on a daily basis. I am so honored to continue to serve as Medical Director and look forward to the future with eager anticipation.